Addex management commentary: H1 2026 net loss holds near CHF 3.5 million as Neurosterix share-of-loss offsets lower R&D spend

• Addex management commentary on the six months ended June 30, 2026 flagged continued losses, with net loss from continuing operations of CHF 3.46 million.
• Operating loss narrowed to CHF 1.13 million as research and development costs fell to CHF 74,000, reflecting no self-funded clinical studies.
• General and administrative costs were steady at CHF 1.07 million, with higher staff costs partly offset by lower professional fees.
• Results were weighed down by CHF 2.33 million share of loss from its 20% equity-method investment in Neurosterix.
• Liquidity remained tight, with CHF 0.8 million cash at June 30, 2026; management cited USD 2.8 million raised post-period via share sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-111142), on September 28, 2026, and is solely responsible for the information contained therein.